Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against symptomatic COVID-19 among immunocompetent individuals testing at a large US retail pharmacy.

Abby E RudolphFarid L KhanAmy ShahTanya G SinghTimothy L WiemkenLaura A PuzniakLuis JodarJohn M McLaughlin

Published in: The Journal of infectious diseases (2023)

BNT162b2 BA.4/5 bivalent showed early additional protection against Omicron-related symptomatic COVID-19, with hybrid immunity offering greater protection.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
systematic review